NEWS RELEASE

Biosensors Establishes German Subsidiary

Mannheim, Germany, 28 April 2011 – Biosensors International has announced the establishment of a subsidiary company in Germany, Biosensors Deutschland GmbH.

The new company will assume direct responsibility for the sales and marketing of Biosensors' interventional cardiology product range in Germany. The flagship product is BioMatrix Flex™, a Biolimus A9™-eluting stent system with abluminal biodegradable polymer, which is rapidly gaining an increasing share of the drug-eluting stent market right across Europe.

Biosensors Deutschland GmbH will commence operations during the German Cardiac Society Congress (DGK) this week in Mannheim. The new company will have its headquarters in Düsseldorf.

"We are delighted to have established a direct sales operation in Germany, one of our most important European markets", commented Biosensors CEO Jeffrey B. Jump.

-Ends-

For further information, please contact:
Richard Kenyon
Biosensors International
+44 7831 569940
r.kenyon@biosensors.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stents and open-heart surgery. It has two separate drug-eluting stent programs, BioMatrix™ and BioFreedom™, a completely polymer-free drug coated stent.

About the BioMatrix™ Stent Family
The BioMatrix™ stent system offers the unique combination of an innovative anti□restenotic drug, BA9™, combined with a biodegradable poly□lactic acid polymer (PLA), abluminally coated onto an advanced, highly flexible stent designed for enhanced deliverability.

Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide over a six to nine month period as the drug elutes, ultimately leaving in place a biocompatible stent surface.